Please login to the form below

Not currently logged in
Email:
Password:

Novartis Oncology

This page shows the latest Novartis Oncology news and features for those working in and with pharma, biotech and healthcare.

Novartis announces positive phase 3 trial results for advanced oesophageal cancer

Novartis announces positive phase 3 trial results for advanced oesophageal cancer

Through a collaboration and licence agreement with BeiGene, Novartis has the rights to develop, manufacture and commercialise tislelizumab in North America, Europe and Japan. ... combinations across additional tumour types that may benefit from an

Latest news

More from news
Approximately 4 fully matching, plus 113 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Novartis created Novartis Oncology in 2016 and Pfizer formed several new business units including specialty care, rare diseases and oncology. ... Novartis/AveXis, are all recent examples of larger companies that have expanded their pipelines in this way.

  • Charting a course for expansion Charting a course for expansion

    David was until recently the head of Baxalta's oncology division, whose formation he led, guiding it through a series of acquisitions and partnering deals. ... Doing so was the latest move in a 25-year pharma career that has also encompassed stints at

  • Choosing destiny Choosing destiny

    For instance, if Novo Nordisk designs a secular grail model by combining IBM's Watson with its own therapies, it will be different from, for example, Novartis' secular grail model combining ... immuno-oncology and companion diagnostics.

  • Deal Watch June 2016 Deal Watch June 2016

    Protein engineering - towards enhanced biologics. Also active in immuno-oncology, Novartis signed a broad collaboration and licence agreement with Xencor worth a potential $2.56bn covering two bispecific, tumour targeting antibodies, ... Tiered low

  • Deal Watch May 2016 Deal Watch May 2016

    Not under pressure as are GSK and Pfizer, Novartis announced the separation of its pharmaceuticals division into two business units: Novartis Oncology and Novartis Pharmaceuticals. ... The pharmaceuticals company will include Novartis' other interests in

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

    Coughlin is a trained oncologist and immunologist with seasoned experience in developing oncology therapeutics. ... This includes serving as executive director of oncology clinical development at Novartis, and asset team leader in early clinical

  • New hires at Bristol-Myers Squibb, Acceleron and FerGene New hires at Bristol-Myers Squibb, Acceleron and FerGene

    Backstrom initially joined Celgene in 2008 as vice president, clinical R&D, with a focus on haematology and oncology. ... He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at

  • Pfizer’s Elizabeth Barrett joins Novartis as its oncology head Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

    She succeeds Bruno Strigini who retires. Novartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland. ... Prior to her time with Pfizer, Barrett held roles with Cephalon andchief executive

  • Novartis Oncology head Bruno Strigini to retire Novartis Oncology head Bruno Strigini to retire

    The head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry. ... Novartis CEO Joseph Jimenez said: "I'd like to thank Bruno Strigini for his contributions and achievements.

  • Rainer Boehm and Hervé Hoppenot join Cellectics board Rainer Boehm and Hervé Hoppenot join Cellectics board

    He said: “Despite many advances in oncology, there remains a need to continue to advance the science to meet the needs of its patients. ... Prior to joining Incyte, Hoppenot was the president of Novartis Oncology and has several senior roles with with

More from appointments
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
foxandcat.online

We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...